PTC Therapeutics | PTCT - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.79B 51.25M 2026-09
Alnylam Pharmaceuticals USD 7.99B 2.44B 2026-09
Amgen USD 96.05B 409M 2026-09
BioCryst Pharmaceuticals USD 591.07M 33.22M 2026-09
Biogen USD 32.05B 32.5M 2026-09
BioMarin Pharmaceutical USD 11.57B 154.21M 2026-09
Cytokinetics USD 1.82B 99.77M 2026-09
Daiichi Sankyo JPY 4.26T 144.08B 2026-09
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Gilead Sciences USD 51.41B 2.05B 2026-09
Incyte USD 7.29B 585.39M 2026-09
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
Ironwood Pharmaceuticals USD 290.59M 5.46M 2026-09
Karyopharm Therapeutics USD 131.42M 23M 2026-03
Novartis USD 117.15B 4.88B 2026-09
Pfizer USD 204.54B 3.41B 2026-09
PTC Therapeutics USD 3.21B 42.76M 2026-09
Puma Biotechnology USD 202.86M 7.95M 2025-09
Roche Holding CHF 98.2B 2.5B 2026-06
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sarepta Therapeutics USD 3.17B 22.45M 2026-09
TG Therapeutics USD 1.64B 110.79M 2026-06
Ultragenyx Pharmaceutical USD 1.19B 77M 2026-09
Vertex Pharmaceuticals USD 32.74B 5.31B 2026-09
Xencor USD 770.5M 45.54M 2026-09